Evidence map›Paper›PMID 40124986›Full record

ArticleRegenerative biomaterials2025

Endocytosis-mediated healing: recombinant human collagen type III chain-induced wound healing for scar-free recovery.

Jian Jin, Haihang Li, Zhengli Chen, Qingsong Liu, Jiqiu Chen, Zihan Tao, Xudong Hong, Yinjia Ding, Yue Zhou, Aifen Chen and 4 more

Abstract read
In one paragraph

Article in Regenerative biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Regenerative biomaterials · 2026
    Article
  10. Research progress on scar-free healing.Annals of medicine · 2025
    Review
  11. Article
  12. Gelatin/hyaluronic acid-basedRegenerative biomaterials · 2025
    Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jian JinState Key Laboratory of Molecular Engineering of Polymers, Department of Macromolecular Science, Fudan University, Shanghai 200438, China.ORCID https://orcid.org/0000-0001-6706-2300
Haihang LiJiangsu Chuangjian Medical Technology Co., Ltd, Changzhou 213100, China.
Zhengli ChenDepartment of Burn Surgery, Changhai Hospital, The Naval Medical University, Shanghai 200433, China.
Qingsong LiuDepartment of Burn Surgery, Changhai Hospital, The Naval Medical University, Shanghai 200433, China.
Jiqiu ChenDepartment of Burn Surgery, Changhai Hospital, The Naval Medical University, Shanghai 200433, China.
Zihan TaoDepartment of Burn Surgery, Changhai Hospital, The Naval Medical University, Shanghai 200433, China.
Xudong HongDepartment of Burns and Plastic Surgery, 903rd Hospital of PLA, Hangzhou 310012, China.
Yinjia DingDepartment of Burns and Plastic Surgery, 903rd Hospital of PLA, Hangzhou 310012, China.
Yue ZhouDepartment of Burns and Plastic Surgery, 903rd Hospital of PLA, Hangzhou 310012, China.
Aifen ChenDepartment of Burns and Plastic Surgery, 903rd Hospital of PLA, Hangzhou 310012, China.
Xudong ZhangDepartment of Burns and Plastic Surgery, 903rd Hospital of PLA, Hangzhou 310012, China.
Kaiyang LvDepartment of Plastic Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
Liangliang ZhuState Key Laboratory of Molecular Engineering of Polymers, Department of Macromolecular Science, Fudan University, Shanghai 200438, China.
Shihui ZhuDepartment of Burns and Plastic Surgery, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scar formation can be effectively prevented when the proportion of collagen type I (Col I)/type III (Col III) is reduced. Unlike Col III, recombinant human collagen type III chain (RHC III chain) does not possess a triple helical structure. This study aimed to elucidate the capacity of fibroblasts to uptake RHC III chain, reduce the Col I/Col III ratio and determine its effects on wound healing and scar. RHC III chain demonstrates qualified cell compatibility. In cell experiments, immunofluorescence and western blot (WB) analyses revealed an increase in the polyhistidine tag level, indicating that RHC III chain in internalized by these cells. Transmission electron microscopy showed increased intracellular phagocytic activity, indicating that RHC III chain enters fibroblasts by endocytosis. The immunofluorescence and WB showed that Col III synthesis enhanced, and Col I/Col III ratio reduced. However, the polyhistidine tag disappeared with time, indicating that RHC III chain degraded within cells and then synthesized into Col III. The content of newly synthesized Col III increases, but real-time fluorescence quantitative showed a decrease in Col III related gene content suggests the formation of negative feedback. However, due to the sufficient raw materials, the amount of Col III synthesis is still increasing, leading to the reduction of the ratio of type I collagen/type III collagen, which beneficial to wound healing and reduce scar hyperplasia. In animal experiments, the SD rat full-thickness skin defect model of wound suggests that RHC III chain also takes effect through endocytosis and ultimately promotes wound healing. The rabbit ear scar model suggests that RHC III chain inhibits scar proliferation by reducing the ratio of Col I/Col III. In summary, RHC III chain was endocytosed by fibroblasts to promote native Col III synthesis, as well as promote wound healing and reduce scar hyperplasia.

Indexed as

collagenendocytosisrecombinant human collagen type III chainscar formation

Identifiers

PMID40124986
PMCPMC11930350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.